Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30672089 | 1.00 | CES2 (0.49) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL7783860 | 1.00 | CES2 (0.49) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL16412814 | 0.83 | CES2 (0.49) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL28998216 | 0.83 | CES2 (0.49) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL30988818 | 0.83 | CES2 (0.49) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL23489619 | 0.83 | CES2 (0.49) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL17660052 | 0.83 | CES2 (0.49) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL16419139 | 0.83 | CES2 (0.49) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL16559381 | 0.82 | SLC6A2 (0.46) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL21680243 | 0.82 | PNMT (0.61) | CES2CES1SLC6A2SLC6A4PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12280023-B2 | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | ATROGI AB (SE) | 2025-04-22 | — | — | US | disclosed |
| CN-118930444-A | Fluorophenyl beta-hydroxyethylamine and its use in the treatment of hyperglycaemia | 阿托基公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-111148731-B | Fluorophenyl beta-hydroxyethylamine and its use in the treatment of hyperglycaemia | 阿托基公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20230364035-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-16 | — | — | US | disclosed |
| US-20230364035-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-16 | — | — | US | disclosed |
| US-20230364035-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-16 | — | — | US | disclosed |
| EP-3681857-B1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-08 | — | — | EP | disclosed |
| EP-3681857-B1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-08 | — | — | EP | disclosed |
| EP-4249054-A2 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2023-09-27 | — | — | EP | disclosed |
| EP-4249054-A2 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2023-09-27 | — | — | EP | disclosed |
| US-11648216-B2 | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | ATROGI AB (SE) | 2023-05-16 | — | — | US | disclosed |
| US-11648216-B2 | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | ATROGI AB (SE) | 2023-05-16 | — | — | US | disclosed |
| US-11648216-B2 | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | ATROGI AB (SE) | 2023-05-16 | — | — | US | disclosed |
| US-20200268688-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2020-08-27 | — | — | US | disclosed |
| US-20200268688-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2020-08-27 | — | — | US | disclosed |
| CN-111148731-A | Fluorophenyl β -hydroxyethylamine and use thereof in the treatment of hyperglycaemia | 阿托基公司 | 2020-05-12 | — | — | CN | disclosed |
| WO-2019053426-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200268688-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | GPR119, SLC5A2, SLC5A1 | CES2 190/4885CES1 323/4885HDAC4 1136/4885 |
| US-12280023-B2 | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | GPR119, SLC5A2, SLC5A1 | CES2 190/4885CES1 323/4885HDAC4 1136/4885 |
| US-20230364035-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | GPR119, SLC5A2, SLC5A1 | CES2 190/4885CES1 323/4885HDAC4 1136/4885 |
| US-11648216-B2 | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | GPR119, SLC5A2, SLC5A1 | CES2 190/4885CES1 323/4885HDAC4 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.